Press release
Alopecia Areata Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Alopecia Areata Pipeline. Dive into DelveInsight's comprehensive report today! @ Alopecia Areata Pipeline Outlook [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Alopecia Areata Pipeline Report
* In January 2025, AbbVie announced a study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo.
* DelveInsight's Alopecia Areata pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Alopecia Areata treatment.
* The leading Alopecia Areata Companies such as Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
* Promising Alopecia Areata Pipeline Therapies such as PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.
Stay ahead with the most recent pipeline outlook for Alopecia Areata. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Alopecia Areata Treatment Drugs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Alopecia Areata Emerging Drugs
* Deuruxolitinib: Concert Pharmaceuticals
Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.
* EQ101: Equillium
EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.
* MAX 40070: Maxinovel Pharmaceuticals
MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.
The Alopecia Areata Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
* Alopecia Areata Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market
Explore groundbreaking therapies and clinical trials in the Alopecia Areata Pipeline. Access DelveInsight's detailed report now! @ New Alopecia Areata Drugs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Alopecia Areata Companies
Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Alopecia Areata Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Alopecia Areata Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Alopecia Areata Market Drivers and Barriers [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Alopecia Areata Pipeline Report
* Coverage- Global
* Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
* Alopecia Areata Pipeline Therapies- PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.
* Alopecia Areata Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Alopecia Areata Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Alopecia Areata Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Alopecia Areata Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Alopecia Areata: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Alopecia Areata- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Deuruxolitinib: Concert Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EQ101: Equillium
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MAX 40070: Maxinovel Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Alopecia Areata Key Companies
* Alopecia Areata Key Products
* Alopecia Areata- Unmet Needs
* Alopecia Areata- Market Drivers and Barriers
* Alopecia Areata- Future Perspectives and Conclusion
* Alopecia Areata Analyst Views
* Alopecia Areata Key Companies
* 27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alopecia-areata-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alopecia Areata Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3966144 • Views: …
More Releases from ABNewswire
New Analysis Reveals Gold IRA Custodian Fee Structures Differ by Up to 315% Acro …
Independent Research from Gold IRA Blueprint Uncovers Significant Cost Disparities That Could Impact Retirement Savings by Thousands Annually
A comprehensive new analysis from Gold IRA Blueprint reveals dramatic variations in fee structures among leading gold IRA custodians, with total annual costs ranging from zero dollars to over $800 per year - a difference of more than 315% that could significantly impact long-term retirement savings.
The six-month research initiative examined fee structures, storage…
BandMGT launches as new system to help bands stay organised
Oxford, UK - BandMGT has just been released as a new band management software platform. It is designed to help musicians keep track of their gigs, setlists, rehearsals, payments and member availability all in one place.
Many bands currently rely on spreadsheets, group chats and a mix of apps to manage their schedules. This often leads to confusion and last minute problems. BandMGT provides a single system to reduce those risks…
Airhub eSIM - The Travel Hack Every Frequent Flyer Should Know
Image: https://www.abnewswire.com/upload/2025/10/01be7b103e3890cb5f7cb4122d5b7a9e.jpg
Travelling to a new country is exciting, but the stress of searching for Wi-Fi just to reach your hotel, or worse, coming home to shockingly high international roaming charges, can quickly ruin your fun. Most of us have been there, and the struggle to find good and less costly connectivity while traveling is all too real.
This is where the convenience of eSIM technology comes in. An eSIM is a…
Professional Tile Cleaners at JP Carpet Cleaning Expert Floor Care Complete Adva …
JP Carpet Cleaning Expert Floor Care announces the completion of IICRC advanced certification for its technicians, strengthening Los Angeles' floor care expertise with eco-friendly methods across 30+ neighborhoods.
Granada Hills-based JP Carpet Cleaning Expert Floor Care [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-30-jp-carpet-cleaning-expert-floor-care-becomes-first-locally-owned-company-to-offer-100-eco-friendly-carpet-cleaning-services-across-greater-los-angeles] announces the completion of an intensive IICRC (Institute of Inspection, Cleaning and Restoration Certification) advanced training program by its professional tile cleaners. The certification program, recognized as the gold standard in the cleaning and…
More Releases for Alopecia
Key Influencer in the Alopecia Market 2025: Rising Prevalence Of Hair Loss Drivi …
What combination of drivers is leading to accelerated growth in the alopecia market?
The rise in hair loss cases is anticipated to fuel the expansion of the alopecia market. Hair loss pertains to either partial or total loss of hair from places where it usually grows. Alopecia treatment is beneficial for alopecia sufferers as it addresses multiple hair loss issues by promoting hair regrowth, devising personalized treatment strategies, implementing combination therapies,…
Global Alopecia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global alopecia market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
The growth of the alopecia market is primarily driven by the rising incidence of alopecia, advancements in treatment options, greater awareness and information accessibility, evolving lifestyle and beauty norms, technological progress, and the growing geriatric population.
Browse 147 Market Data Tables and…
Alopecia Treatment Market - Reclaiming your crown: Alopecia treatment empowering …
Newark, New Castle, USA: The "Alopecia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Alopecia Treatment Market: https://www.growthplusreports.com/report/alopecia-treatment-market/7924
This latest report researches the industry structure, sales, revenue,…
Alopecia Treatment Market - Nurturing Roots, Inspiring Hope: Elevating Alopecia …
Newark, New Castle, USA - new report, titled Alopecia Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Alopecia Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Alopecia Treatment market. The report offers an overview of the market, which…
Global Alopecia Market By Disease type: Alopecia Areata, Cicatricial, Traction, …
According to the latest research by SkyQuest Technology, Global Alopecia Market Size was valued at US$ 8.7 billion in 2021, and it is expected to reach a value of US$ 15.10 billion by 2028, at a CAGR of 8.2% over the forecast period (2022 - 2028). The research provides up-to-date Alopecia Market analysis of the current market landscape, latest trends, drivers, and overall market environment.
Get full report : https://skyquestt.com/report/alopecia-market
The rising…
Alopecia Market Research Report Up to 2031
Visiongain has published a new report on Alopecia Market Report to 2031: Forecasts by Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, and Alopecia Totalis), By Route of Administration (Oral, Topical, and Injectable), By Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/alopecia-market/#download_sampe_div
COVID-19 Impact on Alopecia Market
COVID-19 pandemic has affected more than 200 countries worldwide. Companies have been pressured…
